Matches in SemOpenAlex for { <https://semopenalex.org/work/W4254520110> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4254520110 endingPage "4047" @default.
- W4254520110 startingPage "4047" @default.
- W4254520110 abstract "4047 Background: Despite a recent fall in incidence, gastric cancer remains common in China. 5-FU plus P is a standard treatment for AGC, producing response rates of 27–51% in randomized trials, although few Chinese data are available. We evaluated the efficacy and safety of replacing the 5-FU component with X (Xeloda) as 1st-line therapy in Chinese AGC pts. Methods: We enrolled 145 pts between Jun 2002 and May 2003. All had measurable AGC (WHO), and adequate Karnofsky PS, bone marrow, renal and hepatic functions. Prior radiotherapy or adjuvant chemotherapy was permitted. Patients received capecitabine 1000 mg/m2 orally twice daily on days 1–14 plus fractionated cisplatin 20 mg/m2 i.v. on days 1–5, every 3 weeks. Results: Baseline characteristics of the 130 pts evaluable to date: 98 men, 32 women; median age 53.7 years (range 23–80); median Karnofsky PS 80 (60–100); 82% of pts had 1 metastatic site, and 18% had ≥2, the most common being the lymph nodes (44%), liver (42%), and stomach (17%). The median treatment duration is currently 6 cycles (range 2–6). Efficacy findings are shown in the table: response rate 45% (95% CI, 36–53%). Median progression-free and overall survival have not yet been reached. There were no grade 4 and very few grade 3 adverse events (all <5%): SGPT and SGOT, hand-foot syndrome, nausea, vomiting, anemia, diarrhea, anorexia, anaphylaxis. Most events were easily managed with dose adjustment and/or suitable treatments, except 1 pt with anemia who withdrew after 2 cycles. Conclusions: X combined with fractionated P is highly active and very well tolerated as first-line treatment for AGC, with comparable results to 5-FU/P. These results provide the rationale for randomized testing of the combination, although standard single infusion of P would enhance convenience. No significant financial relationships to disclose." @default.
- W4254520110 created "2022-05-12" @default.
- W4254520110 creator A5008193541 @default.
- W4254520110 creator A5031250085 @default.
- W4254520110 creator A5045607536 @default.
- W4254520110 creator A5059475635 @default.
- W4254520110 creator A5070580494 @default.
- W4254520110 creator A5079263809 @default.
- W4254520110 creator A5079532492 @default.
- W4254520110 creator A5081582906 @default.
- W4254520110 creator A5088072667 @default.
- W4254520110 date "2004-07-15" @default.
- W4254520110 modified "2023-10-16" @default.
- W4254520110 title "Capecitabine (X) combined with cisplatin (P) as 1st-line therapy in Chinese patients (pts) with advanced gastric cancer (AGC)" @default.
- W4254520110 doi "https://doi.org/10.1200/jco.2004.22.90140.4047" @default.
- W4254520110 hasPublicationYear "2004" @default.
- W4254520110 type Work @default.
- W4254520110 citedByCount "0" @default.
- W4254520110 crossrefType "journal-article" @default.
- W4254520110 hasAuthorship W4254520110A5008193541 @default.
- W4254520110 hasAuthorship W4254520110A5031250085 @default.
- W4254520110 hasAuthorship W4254520110A5045607536 @default.
- W4254520110 hasAuthorship W4254520110A5059475635 @default.
- W4254520110 hasAuthorship W4254520110A5070580494 @default.
- W4254520110 hasAuthorship W4254520110A5079263809 @default.
- W4254520110 hasAuthorship W4254520110A5079532492 @default.
- W4254520110 hasAuthorship W4254520110A5081582906 @default.
- W4254520110 hasAuthorship W4254520110A5088072667 @default.
- W4254520110 hasConcept C121608353 @default.
- W4254520110 hasConcept C126322002 @default.
- W4254520110 hasConcept C141071460 @default.
- W4254520110 hasConcept C197934379 @default.
- W4254520110 hasConcept C2776581026 @default.
- W4254520110 hasConcept C2776694085 @default.
- W4254520110 hasConcept C2777063308 @default.
- W4254520110 hasConcept C2777909004 @default.
- W4254520110 hasConcept C2778248108 @default.
- W4254520110 hasConcept C2780580376 @default.
- W4254520110 hasConcept C2780852908 @default.
- W4254520110 hasConcept C509974204 @default.
- W4254520110 hasConcept C526805850 @default.
- W4254520110 hasConcept C71924100 @default.
- W4254520110 hasConcept C90924648 @default.
- W4254520110 hasConceptScore W4254520110C121608353 @default.
- W4254520110 hasConceptScore W4254520110C126322002 @default.
- W4254520110 hasConceptScore W4254520110C141071460 @default.
- W4254520110 hasConceptScore W4254520110C197934379 @default.
- W4254520110 hasConceptScore W4254520110C2776581026 @default.
- W4254520110 hasConceptScore W4254520110C2776694085 @default.
- W4254520110 hasConceptScore W4254520110C2777063308 @default.
- W4254520110 hasConceptScore W4254520110C2777909004 @default.
- W4254520110 hasConceptScore W4254520110C2778248108 @default.
- W4254520110 hasConceptScore W4254520110C2780580376 @default.
- W4254520110 hasConceptScore W4254520110C2780852908 @default.
- W4254520110 hasConceptScore W4254520110C509974204 @default.
- W4254520110 hasConceptScore W4254520110C526805850 @default.
- W4254520110 hasConceptScore W4254520110C71924100 @default.
- W4254520110 hasConceptScore W4254520110C90924648 @default.
- W4254520110 hasIssue "14_suppl" @default.
- W4254520110 hasLocation W42545201101 @default.
- W4254520110 hasOpenAccess W4254520110 @default.
- W4254520110 hasPrimaryLocation W42545201101 @default.
- W4254520110 hasRelatedWork W2352903716 @default.
- W4254520110 hasRelatedWork W2359004531 @default.
- W4254520110 hasRelatedWork W2361930223 @default.
- W4254520110 hasRelatedWork W2365649841 @default.
- W4254520110 hasRelatedWork W2369852829 @default.
- W4254520110 hasRelatedWork W2370474679 @default.
- W4254520110 hasRelatedWork W2380979459 @default.
- W4254520110 hasRelatedWork W2383139818 @default.
- W4254520110 hasRelatedWork W2897258609 @default.
- W4254520110 hasRelatedWork W3122411282 @default.
- W4254520110 hasVolume "22" @default.
- W4254520110 isParatext "false" @default.
- W4254520110 isRetracted "false" @default.
- W4254520110 workType "article" @default.